diabetes mellitus II. non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Pioglitazone 30 mg/daily, orally for 3 months. Intervention 2: Metformin 500mg/bd orally for 3 months.
Treatment - Drugs
Pioglitazone 30 mg/daily, orally for 3 months
Metformin 500mg/bd orally for 3 months
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
21 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diabetic patients (type 2) receiving diet or monotherapy by sulphonylurea, HbA1C=7.5 and FBS=140 Exclusion criteria: known case of inflammatory disease such as IBD, RA, vascultis, recent infection in one month suffering from malignancy, receiving other drug that decrease CRP level .[COX inhibitor (ASA, Celecoxib ), platlete aggregation inhibitor (clopidogrel, abciximab ), lipid lowering agents (Statins, Ezetimibe, Fenofibrate, Niacin, B blockers, antioxidants (vit E), ACEIs, ARBs ,CCBs except Amlodipine, Tamoxifen], Soye isoflavon enriched food; consumption of oral estrogen that increase CRP level, hypersensitivity to Metformin or Pioglitazone, Insulin use, Corticosteroid use, Cr >1.4 mg/dl, severe abnormal liver function test, pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HsCRP. Timepoint: before study and 3 months after treatment. Method of measurement: Kit for CRP_ Latex Inhanced Immunoturbidimetric Assay A Quantitative Test for C-Reactive Protein Determination by Parsazmun company (unitage: mg/L). | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1C. Timepoint: before study and 3 months after treatment. Method of measurement: Kit for HbA1C in whole blood with Immunoturbidimetric Assay, a Quantitative Test by Parsazmun Company (unitage: % ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ramak Ghavam
Qazvin University of Medical Sciences
Outcome results
None listed